Esanex Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Esanex General Information

Description

Developer of an oncology drug intended to offer insights into the role of heat shock protein inhibitors as important anti-cancer agents. The company's drug providesdurable clinical responses in Phase 1b trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors (NET), enabling caregivers to block multiple signaling pathways resulting in improved outcomes for patients.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 115 West Washington Street
  • Suite 1680, South Tower
  • Indianapolis, IN 46204
  • United States
+1 (317)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 115 West Washington Street
  • Suite 1680, South Tower
  • Indianapolis, IN 46204
  • United States
+1 (317)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Esanex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Jul-2019 Completed Out of Business
2. Later Stage VC (Series A) 10-Apr-2017 Completed Generating Revenue
1. Early Stage VC (Series A) 10-Dec-2012 $15.5M $15.5M Completed Clinical Trials - Phase 1
To view Esanex’s complete valuation and funding history, request access »

Esanex Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Esanex’s complete cap table history, request access »

Esanex Patents

Esanex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11492518-B2 Self-adhesive composition for the bonding of substrates with low surface energy Active 28-Oct-2016
US-20190256745-A1 Self-adhesive composition for the bonding of substrates with low surface energy Active 28-Oct-2016
AU-2017331441-A1 Combination therapies using indazolylbenzamide derivatives for the treatment of cancer Inactive 23-Sep-2016
CA-3038064-A1 Combination therapies using indazolylbenzamide derivatives for the treatment of cancer Inactive 23-Sep-2016
EP-3515436-A1 Combination therapies using indazolylbenzamide derivatives for the treatment of cancer Inactive 23-Sep-2016 A61K31/416
To view Esanex’s complete patent history, request access »

Esanex FAQs

  • When was Esanex founded?

    Esanex was founded in 2011.

  • Where is Esanex headquartered?

    Esanex is headquartered in Indianapolis, IN.

  • What industry is Esanex in?

    Esanex’s primary industry is Drug Discovery.

  • Is Esanex a private or public company?

    Esanex is a Private company.

  • What is Esanex’s current revenue?

    The current revenue for Esanex is .

  • How much funding has Esanex raised over time?

    Esanex has raised $18.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process